Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849251 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL4848662 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL3959553 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2HTTNCOA1NCOA3 | |
| SCHEMBL1138691 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2POLBATML3MBTL1 | |
| SCHEMBL1139106 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2POLBATML3MBTL1 | |
| SCHEMBL1139313 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2POLBATML3MBTL1 | |
| SCHEMBL5720839 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBHTTCNR1 | |
| SCHEMBL27220941 | 0.78 | CYP3A4 (0.49) | ALDH1A1SMN1; SMN2CPA1CPB1CPA3 | |
| SCHEMBL27961435 | 0.78 | GGT1 (0.52) | CPA1CPB1CPA3CPB2MMP2 | |
| SCHEMBL19419061 | 0.78 | GGT1 (0.52) | CPA1CPB1CPA3CPB2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050738-B1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | KANEKA CORP (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-7947722-B2 | Imidazolidinone derivative, method of producing the same and method of producing optically active amino acid | KANEKA CORPORATION (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090209768-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | KANEKA CORPORATION (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2050738-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | Kaneka Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209768-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | DAO, RCC2, AADAT | ALDH1A1 2987/4885SMN1; SMN2 4627/4885EPHX2 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.